Sector News

Baxter pads biopharma unit with pre-spinoff oncology buy

May 13, 2015
Life sciences
As Baxter gears up to spin off its biopharma unit into new company Baxalta, it wants to make sure the new pharma has enough revenue to rely on. And to do that, it’s bulking up.
 
The Illinois company has agreed to purchase leukemia treatment Oncaspar from Italy’s Sigma-Tau Finanziaria for $900 million, it said Tuesday. The therapy–part of a first-line chemo regimen to treat acute lymphoblastic leukemia (ALL)–will play a key role in Baxalta’s oncology division, Baxter said, with $100 million in annual sales from countries including the U.S., Germany and Poland.
 
“The acquisition provides an immediate commercial footprint in the United States and Europe with a heritage of expertise in treating this challenging disease,” David Meek, Baxter BioScience’s head of oncology, said in a statement.
 
And Baxter won’t stop there. It plans to investigate Oncaspar for potential new indications, it said, both in ALL and other cancers–including acute myeloid leukemia.
 
Baxter’s not the only company shelling out to get in on the booming oncology market. In March, AbbVie agreed to fork over $21 billion for Pharmacyclics, which markets blood cancer drug Imbruvica with partner Johnson & Johnson. And a few days prior, Novartis  closed its $16 billion pickup of GlaxoSmithKline’s cancer assets.
 
For Baxter, whose biopharma business relies heavily on its hemophilia drugs, cancer meds will be an important sales source. The company thinks the oncology sector represents $10 billion in total market potential for its pipeline assets, it said–and with two new, long-lasting Biogen challengers to its leading hemophilia products out there, that’s revenue Baxalta could use.
 
By Carly Helfand
 

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.